XBI ETF holdings (NYSE) - Page 5 | MetaTrader

展开完整图表

概览所有持仓热图

主要持股 Market Value Shares Weight %

IOVA Iovance Biotherapeutics Inc 60.29 M 14.49 M 0.562%

ABSI Absci Corp 59.94 M 5.17 M 0.558%

NRIX Nurix Therapeutics Inc 59.66 M 2.46 M 0.556%

KOD Kodiak Sciences Inc 58.25 M 1.50 M 0.543%

BHVN Biohaven Ltd 56.41 M 3.79 M 0.525%

VCEL Vericel Corp 53.13 M 1.19 M 0.495%

ANAB AnaptysBio Inc 53.10 M 786.63 K 0.495%

CAPR Capricor Therapeutics Inc 52.45 M 2.18 M 0.489%

STOK Stoke Therapeutics Inc 51.49 M 1.57 M 0.480%

GLUE Monte Rosa Therapeutics Inc 51.15 M 2.11 M 0.477%

VIR Vir Biotechnology Inc 50.39 M 4.95 M 0.469%

PURR Hyperliquid Strategies Inc 49.81 M 6.33 M 0.464%

TYRA Tyra Biosciences Inc 44.47 M 1.39 M 0.414%

CRVS Corvus Pharmaceuticals Inc 43.80 M 2.93 M 0.408%

CGEM Cullinan Therapeutics Inc 43.30 M 2.38 M 0.403%

PGEN Precigen Inc 40.39 M 7.09 M 0.376%

INBX Inhibrx Biosciences Inc 38.00 M 401.03 K 0.354%

TSHA Taysha Gene Therapies Inc 37.90 M 5.57 M 0.353%

ARDX Ardelyx Inc 37.83 M 7.42 M 0.352%

AVTX Avalo Therapeutics Inc 37.51 M 2.03 M 0.349%

1
2
3
4
5
6
7
8

新闻

Gate 合约股票专区将上线 BOT（机器人策略封闭式基金）等 5 个永续合约交易

Oppenheimer维持Inovio制药"跑赢大盘"评级,关注加速审批途径

William Blair维持Compass Therapeutics增持评级,静待试验数据公布

Oppenheimer三月美股策略：动量策略正当时推荐苹果(AAPL.US)、美铝(AA.US)、贝克休斯(BKR.US)等个股

Citizens重申Ideaya Biosciences股票市场表现优于大盘评级

H.C. Wainwright上调Praxis Precision Medicines股票目标价至1,245美元

Oppenheimer重申Capricor股票"优于大盘"评级，维持54美元目标价

Oppenheimer上调Dianthus Therapeutics股票目标价至125美元，此前为62美元

派博桑德勒将Praxis Precision Medicines股票目标价上调至1,200美元

Roth/MKM 对 Arcturus Therapeutics 股票启动覆盖，给予"买入"评级

野村医疗股票获美银重申"跑赢大盘"评级

Wave Life Sciences股价在Arrowhead数据支持INHBE机制后上涨